OPENCORONA: lessons learned from a pandemic vaccine consortium

Early in the COVID-19 pandemic, the EU-funded OPENCORONA project brought together academics, manufacturers, and technology providers in the quest to develop a vaccine. Now, the resulting DNA vaccine is in clinical trials and its developers believe that the ability to induce broad T cell immunity will make it a valuable addition to the current vaccine lineup. Charlotte Barker, Editor, Vaccine Insights, speaks to two of the consortium leaders, Matti Sällberg, Professor, Karolinska Institutet, and Eva-Karin Gidlund, Head of Alliance & Business Development, NorthX Biologics to find out more.  

Please enter your email to access content Read now